(redirected from Alkermes, Inc.)
ALKSAlkermes, Inc. (stock symbol)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Table 1 Fast facts about aripiprazole lauroxil nanocrystal suspension Brand name: Aristada Initio Class: Long-acting injectable atypical antipsychotic (aripiprazole) Indication: Adults with schizophrenia Approval date: June 29, 2018 Availability date: August 1, 2018 Manufacturer: Alkermes, Inc., Waltham, MA Dosing forms: 675 mg IM injection Recommended dosage for schizophrenia: After establishing oral aripiprazole tolerability, administer 675 mg IM along with a single 30 mg oral aripiprazole dose at the time of initiating aripiprazole lauroxil maintenance treatment.
Speakers: Randy Beranek, president and CEO, National Psoriasis Foundation, Arthur Caplan, PhD, Director, Division of Medical Ethics, New York University Langone Medical Center; and Richard Pops, Chairman and Chief Executive Officer, Alkermes, Inc. M&A and Capital Allocation: Everything Old is New Again, this panel brings together CEOs and other senior leaders with firsthand experience navigating the deal landscape while balancing the often conflicting demands of investors, patients, employees and regulators.
AARP Foundation, West Virginia Senior Medicare Patrol Advantage Technology Aegis Sciences Corporation Air Force Health Professions Alkermes, Inc. American Express Ameritas Life Insurance Corporation athenahealth BrickStreet Mutual Insurance Cabell County Medical Society CAMC Physicians Group Urology Cancer Treatment Centers of America Childhelp Eastern Pathology, LLC Highmark of West Virginia Imperial Premium Financing Specialists Janssen Joan C.
The research was supported by Alkermes, Inc., the manufacturer of that medication.
Hoffmann-La Roche Ltd., AstraZeneca PLC, Eli Lilly and Company, Alkermes, Inc., Merck & Co., Inc., Dainippon Sumitomo Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Neurocrine Biosciences, Inc., Gedeon Richter Plc., H Lundbeck A/S, Laboratoires Pierre Fabre SA, Les Laboratoires Servier, Shire Plc, OPKO Health, Inc., Neuralstem, Inc., Suven Life Sciences Ltd., e-Therapeutics plc, Intas Pharmaceuticals Ltd., Angelini Group, Fabre-Kramer Pharmaceuticals, Inc., CeNeRx BioPharma, Inc., Dart NeuroScience LLC, M's Science Corporation, BrainCells Inc., Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Sinil Pharma Ltd., Reviva Pharmaceuticals Inc., Naurex, Inc., PharmaNeuroBoost N.V.
When pharmaceutical company Alkermes, Inc. decided to include treatment professionals in long-term recovery in its "Touchpoints" recovery support campaign for Vivitrol, its medication to treat alcohol dependence, the Cambridge, Mass., company hit on something important.
An expert on tRNA synthetases, Paul Schimmel has also been the co-founder or founding director of numerous successful biotechnology companies, including Sirtris Pharmaceuticals, Alnylam, Repligen Corporation, Alkermes, Inc., Momenta Pharmaceuticals and Cubist Pharmaceuticals, which were taken public on the NASDAQ and are well established as companies that develop and market new medicines.
Alkermes, Inc., Cambridge, Massachusetts, Fairbanks Hospital, Indianapolis, and Witham Health Services, Lebanon, Silver Sponsors.
* Alkermes, Inc., Director, Manufacturing Collaborations
Alkermes, Inc., and Cephalon, Inc., have announced that the FDA has approved VIVITROL[TM] (naltrexone for extended-release injectable suspension) for the treatment of alcohol dependence.
(Nasdaq: CEPH) and Alkermes, Inc. (Nasdaq: ALKS) have entered into an agreement to develop and commercialize Vivitrex (naltrexone long-acting injection) in the United States.